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Abstract 10 
The spreadability of a liquid drug formulation on skin is an indication of it either remaining 11 
stationary or distributing (spreading) as a droplet. Factors determining droplet spreadability of 12 
the formulation are spreading area, diameter of the droplet base, viscosity of the liquid, contact 13 
angle, volume of droplet on skin and any others. The creation of microcavities from the 14 
application of microneedle (MN) has the potential to control droplet spreading, and hence, target 15 
specific areas of skin for drug delivery. However, there is little work that demonstrates spreading 16 
of liquid drug formulation on MN treated skin. Below, spreading of a lidocaine hydrogel 17 
formulation and lidocaine solution (reference liquid) on porcine skin is investigated over MN 18 
treated skin. Controlled spreadability was achieved with the lidocaine hydrogel on MN treated 19 
skin as compared with lidocaine solution. It was observed that the droplet spreading parameters 20 
such as spreading radius, droplet height and dynamic contact angle were slightly lower for the 21 
lidocaine hydrogel than the lidocaine solution on skin. Also, the lidocaine hydrogel on MN 22 
treated skin resulted in slower dynamic reduction of droplet height, contact angle and reduced 23 
time taken in attaining static advancing droplets due to the MN microcavities. 24 
Keywords: Spreadability; Lidocaine; Microneedles; Microcavities; Porcine Skin 25 
1.0 Introduction 26 
Percutaneous absorption/permeation of a drug molecule (e.g., lidocaine) through skin depends 27 
on the contact between the formulation and skin properties through which the drug molecules 28 
are absorbed into different skin layers. The possibility of the drop of a liquid drug formulation 29 
either remaining static or distributing (spreading) horizontally on the skin surface relies on its 30 
spreadability. If the droplet is capable of spreading, then the contact line between the 31 
formulation and skin moves over the skin. The rate of movement of the contact line can be 32 
defined as the spreadability of the formulation.  33 
 34 
Spreadability has significant importance in localised application and efficacy of topical drugs 35 
(Chow et al., 2007). However, the characteristic time scales for spreading of a drug formulation 36 
on skin (~seconds to minutes) is significantly smaller than the characteristic time scales for drug 37 
absorption/permeation into skin (~10s of minutes to hours). Therefore, most studies of 38 
percutaneous or transdermal drug delivery do not characterise spreading behaviour of the drug 39 
formulation over skin. Spreadability is primarily determined by the area/diameter of the 40 
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formulation droplet on a substrate (e.g., skin below), viscosity of the formulation, contact angle, 41 
the volume of a droplet (permeant amount) (Jelvehgari and Montazam, 2011), and other factors. 42 
 43 
Over recent years a number of researchers have discussed the possibility of enhanced 44 
permeation of lidocaine (a common anaesthetic) via a ‘poke and patch’ approach with the help 45 
of solid microneedle (MN) arrays (Banks et al., 2011; Hamzah et al., 2012; Nayak et al., 46 
2014a,b). This approach involves treating the skin with well-defined MNs to create microcavities 47 
in skin followed by the deposition of a droplet of lidocaine solution on the MN treated area. For 48 
example, Nayak et al. (2014a,b, 2015) demonstrated this approach using a lidocaine 49 
NaCMC:gel 1:2.3 hydrogel formulation and determined the permeation profiles of lidocaine in 50 
porcine skin. While the lidocaine droplets spread over the skin, the lidocaine molecules also 51 
permeate through the treated area (Nayak et al., 2014a,b; Nayak et al., 2015). The duration of 52 
lidocaine hydrogel droplet spreading is in seconds, which is much faster as compared with that 53 
for drug permeation which normally takes about an hour to reach equilibrium lidocaine 54 
concentration in skin. 55 
 56 
It is known that MNs have been primarily developed to control the mass transfer distance and 57 
time as a drug molecule is absorbed in the skin. However, the creation of microcavities using 58 
MN to accelerate penetration in the skin (Figure 1) allows controlling of spreading of the drug 59 
formulation droplet on skin and, hence, targeting a specific skin area over which the drug 60 
absorption/permeation can take place. On the other hand, a liquid droplet on a normal skin (i.e., 61 
untreated skin) is likely to spread in a low controlled manner, with low reproducibility and more 62 
rapidly as compared with a MN treated skin. At the moment, there is little or no study that 63 
specifically analyses in detail such spreading dynamics of drug formulation on MN pierced skin 64 
and the role that the MN cavities play in determining the formulation spreading behaviour. This 65 
work aims to address this gap.  66 
 67 
Below, lidocaine was loaded in a hydrogel biopolymer with a gel to NaCMC mass ratio of 2.3 as 68 
discussed earlier in Nayak et al. (2014a,b) and Nayak et al. (2015). This mass ratio represents 69 
optimum drug and vehicle physico-chemical properties for a formulation (Nayak et al., 2014a,b). 70 
For the developed approach, controlling the spreadability of lidocaine hydrogel on skin is 71 
important to acquire liquid distribution of a liquid over the skin surface. A slower droplet 72 
spreading on skin coupled with a faster time in attaining static advancing contact angle is a 73 
favourable outcome in ensuring localised permeation of lidocaine at the treatment site. 74 
 75 
Lidocaine NaCMC:gel 1:2.3 hydrogel is a non-Newtonian liquid at standard room temperatures 76 
and pressure (Nayak et al., 2014a). The Ostwald de Waele power law can be used to describe 77 
the pseudoplastic behaviour of for such a fluid as follows: 78 
 79 
η ൌ k൫γ൯୬ିଵ													 .                  (1) 80 
 81 
Where η is the apparent viscosity, γ is the shear rate, k is the consistency constant of the 82 
substance and n is the power-law or flow index. A log-log plot of viscosity (η) on shear rate (γ) 83 
Page 3 of 11 
 
for lidocaine NaCMC:gel 1:2.3 taken from Nayak et al. (2014a) provides an index value n = 84 
0.392. As the index value is less than 1, the fluid is identified as pseudoplastic (Fang and Hanna, 85 
1999). Its physical property can be exploited in quantifying and controlling the spreading of a 86 
lidocaine hydrogel droplet on an untreated flat skin surface without the need for manual rubbing 87 
across the whole area. For example, the pseudoplastic properties of the hydrogel is likely to 88 
provide a better control in droplet spreading as discussed earlier by Nayak et al. (2014b). 89 
 90 
Below a comparison of spreadability between lidocaine NaCMC:gel 1:2.3 hydrogel (higher 91 
viscosity) and lidocaine solution (lower viscosity) is conducted in order to understand the 92 
spreading behaviour. The loading dosage of lidocaine in both the hydrogel and solution form 93 
containing water was 2.4% w/w. The objective of the study is to examine the spreadability of 94 
lidocaine NaCMC:gel 1:2.3 hydrogel droplets on MN treated and untreated skin in relation to the 95 
viscosity of the formulation. Surface layers of skin treated with MN contain microcavities, which 96 
allow controlling the spreading of the lidocaine hydrogel and achieving static advancing contact 97 
angles and decreased spreading radius faster as compared with untreated skin. Three different 98 
MN types are applied to the skin samples in order to create controlled cavity depths past ~ 99 
15μm thick stratum corneum (SC) layer of skin. Evaporation of the droplet is defined to be 100 
negligible due to the high boiling point of residual paraffin content in the lidocaine hydrogel, and 101 
relatively short duration of the spreading experiments. Our study specifically focuses on a drug 102 
formulation spreading on MN treated skin, which is the first attempt to investigate this process to 103 
the best of our knowledge. 104 
 105 
2.0 Materials and Methods 106 
A lidocaine NaCMC:gel 1:2.3 hydrogel formulated by Nayak et al. (2014a) was adopted for  107 
characterising spreadability on porcine skin. The method of preparation of the hydrogel can be 108 
found in Nayak et al. (2014a,b) and Nayak et al. (2015). As stated earlier, the gel to NaCMC 109 
mass ratio of 2.3 was chosen for this study because of a faster permeation of lidocaine into the 110 
skin. The lidocaine NaCMC:gel 1:2.3 hydrogels were formulated using the vacuum oven method 111 
during final stage evaporation of excess paraffin dissolved in n-hexane as described in Nayak et 112 
al. (2014a,b). To prepare lidocaine solution, lidocaine HCl (> 98% assay) was added to 113 
deionised water and heated gently to ensure a dissolved solution at 2.4% w/w. However, no 114 
lidocaine permeability experiments were conducted below. This work is focussed on 115 
determining the spreading radii, droplet heights, dynamic contact angles and characteristic 116 
spreading times of lidocaine hydrogel and solution (i.e., lidocaine dissolved in deionised water) 117 
on both porcine skin and an artificial skin membrane, namely, Strat-M.   118 
 119 
2.1 Reagents and Materials 120 
Lidocaine HCl (Sigma Aldrich UK, Dorset, UK), lidocaine NaCMC:gel 1:2.3 hydrogels, 121 
autopipette 0-10 µl (Thermofisher Ltd, Warrington, UK), Camera i-speed LT high speed video 122 
(Olympus, Essex, UK), MNs (AdminPatch, California, U.S.A), porcine skin (local butcher, UK), 123 
piston enabled pressure/force device (SMC pneumatics Ltd, Buckinghamshire, UK), synthetic 124 
transdermal membrane (Strat-M™, Merck Millipore, Hertfordshire, UK), temperature and 125 
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humidity probe (Standard, Maplin Electronics, Leicestershire, UK) were used in experiments 126 
below. 127 
 128 
2.2 Preparation of skin for spreading experiments 129 
The procedures for skin preparation were similar to the ones used for Franz diffusion cell (FDC) 130 
experiments for determining drug permeation in skin, e.g., please see methods stated by Nayak 131 
et al. (2014a,b). Briefly, these procedures involved the following steps: (i) either fresh porcine 132 
skin pieces originating from the porcine ears were washed in deionised water and dried using a 133 
tissue, or frozen porcine skin pieces originating from the porcine ears were thawed at room 134 
temperature, washed in deionised water and dried using a tissue; (ii) the cartilage, 135 
subcutaneous fat, blood vessels and connective tissue were removed from the underlying 136 
dermis sections of all skin samples; (iii) the skin samples were dissected further into 10 mm x 10 137 
mm square pieces; (iv) the skin was placed on microscope slides with SC layer facing upwards 138 
for observation of the spreading dynamics.  139 
 140 
2.3 MN treatment of skin 141 
Stainless steel MNs of two lengths (1100μm and 600μm) were placed in the centre of a 142 
prepared porcine skin sample. A perpendicular piston barrel device (SMC pneumatics Ltd, serial: 143 
CD85N16-50-B) was used for transmission of controlled pressure induced force onto the 144 
chosen MN as described by Cheung et al. (2014). Using the system, constant pressures of 0.5 145 
bar, 1.0 bar and 2.0 bar equating to impact forces of 3.9 N, 7.9 N and 15.7 N were held for five 146 
minutes on the base of the MN (Nayak et al., 2015; Cheung et al., 2014). The forces (3.9 N, 7.9 147 
N and 15.7 N) used to treat the skin with the MNs (Nayak et al., 2015). The MN patch was 148 
removed from the porcine skin prior to droplet spreading experiments. 149 
 150 
2.4 Spreading of lidocaine NaCMC:gel 1:2.3 over skin surface 151 
The experimental procedures for studying the spreading of lidocaine hydrogel droplet on 152 
porcine skin were adapted from Chao et al. (2014). A lidocaine hydrogel droplet (volume of 3.0 153 
± 0.5 μl) was deposited using a pipet onto a piece of skin resting on a microscope slide as 154 
carefully as possible to prevent splashing or fast inertial spreading. The i-speed LT high speed 155 
camera (Olympus, UK) recorded 1.85 frames per second until a stationery droplet profile or full 156 
disappearance was reached. The procedure was repeated twice for the control lidocaine 157 
solution. The real time capture of stages of the droplet spreading by camera configurations (i-158 
speed, LT high speed) focused on the droplet is presented in Figure 2. This arrangement is 159 
based on liquid spreading and imbibition experiments for Newtonian liquids (Chao et al., 2014)   160 
 161 
2.5 Spreading of lidocaine NaCMC:gel 1:2.3 hydrogels on the surface of artificial skin 162 
Strat-M membrane  163 
Besides porcine skin, synthetic membrane which is sometimes used as a substitute for skin in 164 
transdermal in vitro studies were used as a substrate. These are composed of polyethersulfone 165 
and polyolefin and are known by the trade name Strat-M (Merck Millipore Ltd, Hertfordshire, 166 
UK). Strat-M membranes were chosen as control matrices for spreadability studies because of a 167 
relatively uniform flat surface as compared with the less uniform and rough surfaces of natural 168 
skin samples.  169 
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 170 
The characterisation of droplet spreading parameters, especially contact angles, was adopted 171 
from Chao et al. (2014). A square section of membrane substrate (15 mm x 15 mm) from a 172 
larger section was cut and taped to an edge of the glass side. This allows closer distance and 173 
improved resolution between the droplet and the camera lens. A hydrogel droplet of volume 3.0 174 
± 0.5 μl was immediately deposited on the membrane in the same way as in the case a natural 175 
skin. The recording procedure was identical to that described in the previous section. The 176 
droplet images of all formulations used were processed using Vision Builder software (National 177 
Instrument, UK) to determine droplet spreading parameters: contact angle, droplet height and 178 
spreading radius.  179 
 180 
2.6 The measurement of relative humidity and temperature 181 
The percentage relative humidity (% RH) and temperature of the droplet environment were 182 
recorded using an electronic probe (Standard, Maplin Electronics, Leicestershire, UK). The data 183 
were acquired in triplicate.  184 
 185 
3.0 Results and Discussion 186 
 187 
Comparative trends for lidocaine droplet spreading on porcine skin samples and Strat-M 188 
membrane were deduced starting with lidocaine solution as a control sample. The results are 189 
discussed below. 190 
 191 
3.1 Spreadability of lidocaine 2.4 % w/w solution (lidocaine dissolved in DI water)  192 
 193 
The spreading of lidocaine 2.4% w/w solution droplets on normal skin (i.e., untreated porcine 194 
skin) were significantly more rapid and showed an almost linear dependence of spreading 195 
radius on time as compared with those for MN treated skin (Figure 3a). Likewise, the droplet 196 
heights of lidocaine solution droplets showed faster reduction and the droplet heights at static 197 
profiles was achieved after approximately 130 seconds (Figure 4a). The dynamic contact angle 198 
for the same case showed a faster reduction reaching the static advancing contact angle 199 
approximately of 11˚ after 130 seconds (Figure 5a). A sharp reduction in the contact angle was 200 
observed within the first 40 seconds for the lidocaine solution on the untreated skin. This 201 
suggests a slightly steeper reduction profile as compared with that for the lidocaine solution on 202 
3.9 N MN treated skin for MNs of 600 and 1100μm lengths, respectively (Figure 5d). The 203 
microcavity depths for both 600μm and 1100µm long MNs are expected to be shallow for the 204 
force applied on the MNs (Nayak, et al., 2015) and, therefore, significantly less reduction in the 205 
contact angles was observed when compared with those for non-MN treated skin (Figure 5c). 206 
 207 
Droplets of the lidocaine solution have an initial contact angle of 57.1° at the moment of 208 
deposition (t0) on the non-MN treated skin. The viscosity of lidocaine solution is very similar to 209 
DI water and both are Newtonian fluids. However, the initial contact angle was near 90° for DI 210 
water on non-MN treated skin as reported earlier by Elkhyat et al. (2004), which is significantly 211 
higher than observed for the lidocaine solution. The high contact angle of DI water was caused 212 
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by the low sebum content on skin and there is a big variation in the initial contact angle 213 
depending on skin location (Elkhyat et al., 2004). Sebum is a natural mixture of lipids. Lidocaine 214 
solution on non-MN treated skin is devoid of artificial cavities and excess liquid cannot retain 215 
inside cavities and slow down droplet spreading. 216 
 217 
The 1100 µm long MN induced microcavity depths for 3.9 N, 7.9 N and 15.7 N forces are 218 
reported to be 19.5 µm, 23.1 µm and 26.7 µm, respectively (Nayak et al., 2015). The mean 219 
microcavity depths using 600 µm long MN for the same forces are small but they are not easily 220 
detectable for transverse visualisation of skin microcavities as the forces applied are relatively 221 
small (implying smaller microcavity length). However, AdminPatchTM microneedles at 600μm 222 
length are shown to increase drug permeation. For example, drug permeability studies by Kaur 223 
et al. (2014) demonstrated a 14.3 fold increase in permeation flux as compared with passive 224 
diffusion for the transdermal delivery of an anti-hypertensive agent, thus implying that 225 
microcavities were formed in skin. These depths cross the typical SC layer depth of 15 µm 226 
(Nayak et al., 2015).  227 
 228 
The dynamic contact angles of lidocaine solution on 7.9 N force treated MN skin outlines slow 229 
decreases in contact angles, which is especially more significant for the 1100 μm long MNs 230 
(Figure 5a). The spreading radius and droplet height of lidocaine solution are significantly less 231 
for 7.9 N force treated skin (Figures 3a and 4a). This is because of deeper MN cavities 232 
capturing excess liquid during droplet spreading of lidocaine solution. Nevertheless, it was not 233 
possible to determine using conventional cryotome techniques if a large quantity of MN in a 234 
patch created a uniform depth microcavity for both specific MN lengths. MNs were impacted on 235 
skin for 5 minutes maximum using one specific force, so an assumption that most MNs have 236 
successfully pierced skin at significant microcavity depths will be made here. 237 
 238 
3.2 Spreadability of lidocaine NaCMC:gel 1:2.3 hydrogel 239 
The spreading of lidocaine NaCMC:gel 1:2.3 hydrogel show similar trends for 600µm long MN 240 
treated skin, particularly closer for 3.8 N and 7.8 N forces (Figure 3c). The fluid properties of the 241 
formulation which affect the spreading behaviour have been discussed earlier (Nayak et al., 242 
2014a, b). 243 
 244 
The 15.7 N force on a 600µm MN patch treated skin showed increasing spreading radius than 245 
3.9 N as compared with the lowest force of the same MN length (Figure 3c). This is because the 246 
MN cavity depths are likely not to be deep enough. The reason is because of an observable 247 
reduction in spreading radius caused by deeper micro-cavities from higher MN forces. Lidocaine 248 
hydrogel droplets for the insertion forces of 3.9 N, 7.9 N and 15.7 N for 1100 µm long MNs 249 
provide less rapidly increasing spreading radius, less rapidly decreasing droplet heights and 250 
less rapidly decreasing dynamic contact angles (Figures 3c, 4c and 5c) before  static profiles 251 
were reached. Nevertheless, there were minor contradictions in reporting lower spreading radii 252 
when droplet heights were not decreasing rapidly because of the mild pseudoplastic properties 253 
of the lidocaine hydrogel (Nayak et al., 2014a). For example, lidocaine hydrogel from 3.9 N, 254 
600µm treated skin should hypothetically outline faster spreading than 7.9 N, 1100µm on skin 255 
because the latter usually possess deep microcavites (Figure 3c). Skin microcavities created by 256 
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MNs do not produce exact replicates of microcavity lengths as shown in transverse section 257 
micrographs due to variability in the viscoelastic property of skin (Nayak et al., 2015). Further, 258 
lidocaine hydrogel droplets were sometimes difficult to dispense with accurate volumes within ± 259 
0.05 μl because of the viscous nature of the formulation. 260 
 261 
The results show that the lidocaine solution spreading radii for 3.9 N and 7.9 N forces of 1100 262 
µm long (longer MNs) MN is distinctly different as compared to the lidocaine hydrogel spreading 263 
radii (Figures 3a and 3c). However, no significant difference in droplet spreading radii was 264 
observed when comparing 3.9 and 7.9 N force of 600 µm long MN (shorter MNs) for lidocaine 265 
solution (Figure 3a). In further scrutinising spreading patterns the lidocaine solution showed 266 
rapid spreading, faster decrease in droplet height and rapid decrease in dynamic contact angle 267 
as compared with lidocaine hydrogel when the same forces, namely, 3.9 N force was applied on 268 
the skin (Figure 3d). 269 
 270 
The artificial membrane (Strat-M), which is normally implemented in drug based in vitro passive 271 
diffusion studies, was a control for skin because of a relatively smooth surface (Uchida et al., 272 
2015). The spreading radii of lidocaine solution and hydrogel droplets could not be measured 273 
reliably with a good repeatability because of the horizontal placement of camera and liquid 274 
percolation through the pores in the membrane. However, there is a slight decrease in droplet 275 
height and dynamic contact angle for lidocaine solution droplets (Figures 4b and 5b). This slight 276 
decrease can be attributed to the percolation of lidocaine solution into Strat-M pores despite no 277 
significant change in droplet spreading radius. 278 
 279 
Lidocaine hydrogel droplets showed significant change in spreading radius, droplet height and 280 
dynamic contact angle (Figures 4b, 5b) on Strat-M. The droplet spreading was likely to be 281 
caused by the lower surface tension of lidocaine hydrogel on the hydrophobic surface of Strat-M. 282 
Lidocaine hydrogel contains residual paraffin of low surface tension properties as compared 283 
with water. 284 
 285 
Lidocaine hydrogels and lidocaine solution droplets snapshots outline spreading in terms of 286 
observed changes in droplet shape at three distinct timings (Figures 6 and 7). Lidocaine 287 
solution droplets have dome shape at the initial time of placement as compared with slightly 288 
flattened dome shaped droplets for lidocaine hydrogel (Figures 6 and 7). After a duration of 10 289 
seconds, the lidocaine hydrogels spread more than the lidocaine solution, especially on skin 290 
treated with 600 μm long MNs (Figures 6 and 7). In most cases, lidocaine solution shows 291 
distinct droplet with respect to 7.9 N force with 1100μm long MN treated skin and Strat-M 292 
membrane after 180 seconds (Figure 6). The remaining MN treated skin variables appear not to 293 
retain more lidocaine solution droplets in the microcavities (Figure 6). After the duration of 180 294 
seconds, the droplet outline is distinctly notable for lidocaine hydrogel after 1100μm MN 295 
treatment on skin (Figure 7). 296 
 297 
The relative humidity and temperature of the surrounding vicinity for droplet spreadability was 298 
48.6±4.31% at 20.1˚±2.40˚C, respectively. The standard deviation for relative humidity is 299 
observed because the surroundings are not an isolated system preventing the transfer of heat. 300 
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Normal environmental changes in relative humidity were expected because the duration of 301 
experiments were conducted upto 3 minutes and relative humidity can fluctuate in a matter of 302 
seconds. The reading of relative humidity of 48.6% is near average at a low room temperature. 303 
The likelihood of evaporation is low for these surrounding conditions and the short duration of 304 
the experiments.  305 
 306 
3.3 Dimensionless spreading parameters of lidocaine hydrogel and solution 307 
The spreading dynamics of lidocaine NaCMC:gel 1:2.3 hydrogel and solution are represented in 308 
this section in terms of dimensionless parameters, namely, dimensionless spreading radius ( ୐౪୐ౣ), 309 
dimensionless contact angle (
θ౪
θౣ
), dimensionless droplet height ሺ ୦౪୦ౣሻ and dimensionless 310 
spreading time ( ୲୲∗) and dimensionless droplet volume ቀ
୚౪
୚ౣ౗౮ቁ. For the above five dimensionless 311 
parameters, the numerators, namely, Lt, θt, ht, Vt and t, are the droplet spreading radius, contact 312 
angle, height, volume and measured time periodically at different time intervals. On the other 313 
hand, the denominators of the fractions are the droplet base showing the maximum spreading 314 
radius, maximum contact angle, maximum droplet height, maximum droplet volume and static 315 
advancing droplet time. The dimensionless numbers, namely, ୐౪୐ౣ, 
θ౪
θౣ
 , ୦౪୦ౣ and 
୚౪
୚ౣ౗౮ are plotted 316 
as function of ୲୲∗ for various circumstances (Figure 8). Analyses of these parameters provide 317 
understanding of the time evolution of these parameters and give some generality to the results 318 
(e.g., see Chao et al., 2014). Figure 8 shows that the time evolutions of these dimensionless 319 
parameters are different implying that the spreading behaviour is different in different cases. 320 
These are discussed below. 321 
 322 
The lidocaine hydrogel spreading on 3.9 N and 7.9 N force treated skin with 1100μm and 600 323 
µm long MN showed short durations in increasing dimensionless spreading profiles, thus 324 
attaining closeness to a plateau of dimensionless value of 1.0 at a shorter time interval (Figure 325 
8a). The lidocaine solution on non-MN treated skin could not be reported as dimensionless 326 
spreading because a linear profile was observed and Lm could not be deduced because of no 327 
plateau (Figure 3a). 328 
 329 
The spreading of lidocaine hydrogels on 7.9 N and 15.7 N force treated skin with 1100 µm long 330 
MN showed a long durations in increasing spreading radius; thus, attaining closeness to 331 
dimensionless value 1.0 above the fractional time of 0.90 (Figure 8a). A short duration in 332 
increasing dimensionless spreading means a less dynamic spreading across the skin. As 333 
mentioned earlier in this paper, the lidocaine hydrogel fill the skin microcavities and the 334 
spreading of the hydrogel slow down.  335 
 336 
All lidocaine hydrogels droplets on MN treated skin outlined slower reduction of dimensionless 337 
droplet height as the liquid fills the microcavities on MN treated skin (Figure 8b). Comparatively, 338 
the lidocaine solutions showed faster dynamic height reduction from maximum spreading height 339 
(t = 0) because of high initial droplet height fractions and faster spreading (Figure 8b). 340 
 341 
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Slower dynamic reduction of contact angle was observed for all lidocaine hydrogel droplets on 342 
MN treated skin (Figure 8c). The lidocaine hydrogel on 3.9 N of 1100 μm length, 7.9 N and 15.7 343 
N of 600 μm treated skin showed slightly slower reductions in fractional contact angles (Figure 344 
8c). Nevertheless, lidocaine hydrogel on 7.9 N and 15.7 N treated skin samples with 1100 μm 345 
long MN outlined slightly faster reductions in the dimensionless contact angle (Figure 8c). Static 346 
advancing droplets were found to arrive at shorter fractional timings for lidocaine hydrogels 347 
because of the viscous property of the hydrogel and presence of numerous MN microcavities as 348 
liquid percolates into the microcavity spaces.  349 
 350 
The lidocaine solution droplets show significantly more dynamic volume decreases as 351 
compared with lidocaine hydrogel droplets (Figure 9 a,b), which is due to the fact that the 352 
lidocaine solution percolates into the MN holes faster than the lidocaine hydrogel droplets. The 353 
lidocaine hydrogels outline low droplet volume reductions in microneedle treated skin and fast 354 
appearance of static droplet volumes (Figure 9b). There was a faster reduction in droplet 355 
volume for Strat-M and 15.7 N, 1100 μm treated skin (Figure 9b).  The roughness of skin and 356 
the pseudoplastic properties of the hydrogel are two factors in explaining the likelihood for the 357 
observed static advancing droplet profiles. Non-microneedle treated skin and Strat-M 358 
membrane surfaces appear smooth, so there appears to be faster droplet volume decreases in 359 
those two substrate control parameters. 360 
   361 
4.0 Conclusion 362 
The spreading of a liquid drug formulation, namely, lidocaine NaCMC:gel 1:2.3 hydrogel, on MN 363 
treated skin is studied. The results of the study show improved control of the formulation 364 
spreadability as compared to those for lidocaine solution (lidocaine dissolved in deionised water) 365 
alone. Lidocaine NaCMC:gel 1:2.3 hydrogel show a slightly lower spreading radius, sight 366 
decrease in droplet height and smaller, controlled decrease in dynamic contact angle as 367 
compared with lidocaine solution. The slower dynamic reduction of droplet height and contact 368 
angle and convergence to static advancing droplet at short initial timings for lidocaine 369 
NaCMC:gel 1:2.3 hydrogel are indication of the seepage of the liquid inside MN microcavities in 370 
skin.  371 
  372 
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Figure 1. A liquid droplet on microneedle treated matrix and percolation of liquid into microcavities. The 
arrows illustrate droplet spreading radius (L), droplet height (h) and contact angle (θ).  
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Figure 2. A schematic diagram of experimental setup for the capture of droplet spreading 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3. Time evolutions of droplet spreading radius for a) lidocaine solution on microneedle and non-microneedle 
treated skin b) lidocaine microgels on microneedle treated skin c) lidocaine solution and lidocaine microgels on 
microneedle treated skin. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.  
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 Figure 4. Time evolutions of droplet height for a) lidocaine solution on microneedle and non-microneedle 
treated skin b) lidocaine solution and lidocaine microgels on Strat-M membrane c) lidocaine microgels on 
microneedle and non-microneedle treated skin d) lidocaine solution and lidocaine microgels on microneedle 
treated skin. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.   
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Figure 5. Time evolutions of dynamic contact angle for a) lidocaine solution on microneedle and non-
microneedle treated skin b) lidocaine solution and lidocaine microgels on Strat-M membrane c) lidocaine 
microgels on microneedle and non-microneedle treated skin d) lidocaine solution and lidocaine microgels on 
microneedle treated skin. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.   
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Figure 6.  Captured images of lidocaine solution droplets (C) on a substrate (skin or membrane) at three 
different time points. The figure shows the droplet morphology at the substrate for different forces of MN 
insertion and MN lengths which were used to treat the skin. 
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Figure 7. Captured images of lidocaine NaCMC:gel 1:2.3 hydrogel droplets (S) on a substrate (skin or 
membrane) at three different time points. The figure shows the droplet morphology at the substrate for 
different forces of MN insertion and MN lengths which were used to treat the skin. 
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Figure 8. The lidocaine droplet plots outlining dynamic variation in a) spreading of hydrogel (S) or solution (C) 
on microneedle and non-microneedle treated skin b) droplet height of hydrogel (S) or solution (C) on 
microneedle and non-microneedle treated skin c) contact angle of hydrogel (S) or solution (C) on 
microneedle and non-microneedle treated skin. 
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Figure 9 The non-dimensional droplet volume on top of skin sample a) for lidocaine solution b) lidocaine 
NaCMC:gel 1:2.3. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.   
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